Close

Needham & Company: Specialty Pharmaceuticals - 2012 Preview: European Hangover Expected to Ease; Valuations Reflect Fear Not Fact Dec 20, 2011 08:01AM
Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); 3Q11 Meets Expectations as Key Products Continue Strong Pace Nov 3, 2011 08:10AM
Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Confirms Purchase of Divested Teva-Cephalon Products for Bargain Price Oct 19, 2011 08:27AM
Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Positive Outcome for Par as a Result of Teva-Cephalon Merger Oct 10, 2011 08:06AM
Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Whistleblower Lawsuit Accuses Par of Illegal Drug-Switching Scheme Sep 7, 2011 08:38AM


Jul 26, 2011 09:15AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Threat Finally Emerges on Megace ES; Longer Term Overhang With No Immediate Bite
Jun 30, 2011 08:50AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Zuplenz & Oravig Life Support Terminated; Restructuring Removes Overhang
Jul 19, 2010 07:49AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL) and Par Pharmaceutical (PRX)
Jul 6, 2010 07:39AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Zuplenz Approval Adds Another Product to Strativa Product Portfolio
May 27, 2010 07:56AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Receives Final FDA Approval for Generic Zegerid
Apr 15, 2010 08:01AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Court Invalidates Zegerid Patents; Adding more Visibility and Certainty to a Key Pipeline Opportunity
Sep 25, 2008 07:55AM Needham & Co Initiates Coverage on Drugs - Generic